Authors: Dogrukol-Ak, Dilek; Tore, Fatma; Tuncel, Nese

Source: Current Drug Metabolism, Volume 10, Number 12, May 2004 , pp. 1325-1340(16)

Publisher: Bentham Science Publishers

Abstract:

In recent years, VIP / PACAP / secretin family has special interest. Family members are vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), secretin, glucagon, glucagon like peptide-1 (GLP1), GLP2, gastric inhibitory peptide (GIP), growth hormone releasing hormone (GHRH or GRF), and peptide histidine methionine (PHM). Most of the family members present both in central nervous system (CNS) and in various peripheral tissues. The family members that are released into blood from periphery, especially gut, circulate the brain and they can cross the blood brain barrier. On the other hand, some of the members of this family that present in the brain, can cross from brain to blood and reach the peripheral targets. VIP, secretin, GLP1, and PACAP 27 are transported into the brain by transmembrane diffusion, a non-saturable mechanism. However, uptake of PACAP 38 into the brain is saturable mechanism. While there is no report for the passage of GIP, GLP2, and PHM, there is only one report that shows, glucagon and GHRH can cross the BBB. The passage of VIP / PACAP / secretin family members opens up new horizon for understanding of CNS effects of peripherally administrated peptides. There is much hope that those peptides may prove to be useful in the treatment of serious neurological diseases such as Alzheimer's disease, amyotropic lateral sclerosis, Parkinson's disease, AIDS related neuropathy, diabetic neuropathy, autism, stroke and nerve injury. Their benefits in various pathophysiologic conditions undoubtly motivate the development of a novel drug design for future therapeutics.

Keywords: secretin family; blood-brain barrier; vasoactive intestinal peptide; pituitary adenylate cyclase-activating polypeptide; gastric inhibitory peptide; peptide histidine methionine

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1381612043384934

Affiliations: 1: Anadolu University, Faculty of Pharmacy, Department of Analytical Chemistry, 26470 Eskisehir, Turkey.

Publication date: 2004-05-01

More about this publication?

• Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.
  
  Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Dogrukol-Ak, Dilek ;  Tore, Fatma ;  Tuncel, Nese

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers